Pharsight

Relistor generic

Relistor is an anti-constipation drug owned by Salix Pharmaceuticals. It contains the active agent methylnaltrexone bromide and is available in solution form for subcutaneous use. The drug was first authorized for market use on 24 April, 2008. It is protected by 8 patents, none of which have expired.

When will Relistor generic be available?

The generic versions of Relistor are anticipated to become available after 31 December, 2030. This is because the final patent protecting Relistor expires on that day, clearing the way for generic entry.

Relistor uses

Relistor is primarily utilized for the treatment of opioid-induced constipation. Its active ingredient, methylnaltrexone bromide, effectively counters the constipating effects of opioids on the digestive system.

Relistor patent expiration

Relistor is guarded by eight key patents. The last of these, titled 'Peripheral opioid receptor antagonists and uses thereof', is due to expire on 31 December, 2030. Consequently, this is the earliest possible date for the availability of Relistor generic. Below are the details of the patents:

EPO Oppostions filed on Relistor

Relistor dosage

Want to ask something?